DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Texas aids sheltering evacuees in accessing prescription medications
September 12, 2017

Consideration of the Texas model medication coverage for evacuees in shelters is under consideration in Florida Continue reading


Operating in Florida under Emergency Executive Orders
September 8, 2017

Find out how to volunteer and know the restrictions regarding advanced supplies of Schedule II controlled substances. Continue reading